ARRY-380 is a potent and selective HER2 inhibitor with IC50 of 8 nM.
Targets
HER2
IC50
8 nM
In Vitro
ARRY-380 is equipotent against truncated p95-HER2 with IC50 of 7 nM. [1] However, ARRY-380 suppresses EGFR with IC50 of 4 μM. ARRY-380 is about 500-fold selective for HER2 versus EGFR. [1]
In Vivo
ARRY-380 significantly prevents the growth of tumor in multiple HER2-dependent tumor xenograft models and displays additive activity in combination with standard-of-care agents. [1]
Clinical Trials
ARRY-380 is in a phase I clinical trial for the treatment of breast cancer.